Introduction
Long-term antiepileptic drugs (AEDs) remain the mainstay of epilepsy treatment. AEDs eliminate or reduce seizure frequency in up to 67% of patients. 1 Medication treatment for chronic diseases, such as epilepsy, requires that patients incorporate complex medication regimens into their daily routines. Managing medication schedules may pose a significant burden in patients' lives. 2 AED choice should therefore be tailored to patients' factors that may limit medication use, such as tolerability, treatment adherence and side effect profile. Non-adherence to medication treatment regimens is a worldwide health problem. Non-adherence rates among patients with epilepsy range from 30% to 50%. 3 Clinicians treating patients with epilepsy note that non-adherent patients report more difficulty in attaining seizure control compared to adherent patients. Uncontrolled seizures lead to major morbidity and mortality, including not only physical injury, such as head trauma, fractures and burns, but also psychosocial problems, such as depression, anxiety disorders, decreased quality of life, and sudden unexpected death. Even though educating patients to strictly follow medication regimens is key to epilepsy treatment, 3 intentional non-adherence may also interfere with seizure control. 4 Lack of seizure control is influenced by epilepsy etiology, seizure type, comorbidities, and treatment non-adherence. 5 Treatment adherence is affected by individual patient factors (demographic and socioeconomic features, as well as perception and beliefs about epilepsy), disease features (seizure frequency and severity), medication use (number of daily doses and side effects), and factors related to patient-provider relationship. 6 Seizure control is also affected by the treatment gap, defined as the proportion of people with epilepsy who require treatment but do not receive it. Treatment gap is influenced by access to and quality of medical care, as well as cultural differences and stigma associated with epilepsy.
epilepsy. Identifying adherence related factors allows development of strategies to improve treatment adherence, with consequent better seizure control.
We studied treatment non-adherence factors in patients with epilepsy and determined its association with patients, disease, treatment features, as well as with social support issues.
Methods
The study was approved by the institutional review board (CAPPesq, Process number 210/09), and was performed in accordance with the 1964 Declaration of Helsinki (and succeeding revisions) ethics parameters. Written informed consent was obtained from all patients prior to study inclusion. Anonymity was assured. This is a prospective, cross-sectional study using descriptive and correlation analyses, conducted in an epilepsy outpatient clinic in a university-affiliated, tertiary referral hospital in São Paulo, Brazil. This clinic receives referrals from other specialty clinics from the Hospital Complex and from neurologists in the public system. Most patients are referred if patients' seizures are not controlled after perceived optimal treatment with antiepileptic drugs. Since January 2002, 4882 new cases have been evaluated, and, as of July 2012, 1851 patients were followed in the clinic. Patients who attain seizure control or are considered optimally controlled are counter-referred to the original service. This clinic population is, therefore, heavily biased toward very refractory epilepsy cases.
Eligibility criteria were: diagnosis of epilepsy according to the International League Against Epilepsy (ILAE) criteria, 8 age !18
years, independence in daily living activities, and absence of major cognitive impairment or active psychiatric disorders. These inclusion criteria were chosen to ensure that patients would be able to understand and respond to questions from the study instruments, which were read to the patient. Exclusion criteria were: presence of a rapidly progressing neurological or medical disorder, history of psychiatric syndromes that could limit participation, coexisting non-epileptic psychogenic seizures, patients not receiving AEDs, and a history of significant substance abuse within the past year. Sampling was nonrandom. Patients were invited to participate while waiting for the medical consult on Epilepsy Clinic days. All patients fulfilling eligibility criteria, and who attended the epilepsy clinic after study onset were included in the study, until the estimated enrolment number of patients was reached. All patients who met eligibility criteria and attended the epilepsy clinic between July 2009 and February 2010 (n = 385 patients) were included in the study.
Sample size calculation
To calculate sample size, non-adherence rate was chosen as the primary endpoint. We calculated a conservative sample size, assuming a 50% non-adherence rate, with a 95% confidence interval and a 5% significance level. This yielded a sample size of 385 patients. 9 Therapeutic adhesion was considered the dependent variable. Morisky-Green Test was used to assess treatment adherence. 10 This is a simple four-item questionnaire assessing non-adherence behavior. Adherence was classified as high if all four questions were answered as ''no'', moderate if one or two questions were answered as ''yes'', and low if more than two questions were answered as ''yes''. Patients with moderate or low adherence were considered non-adherent.
Independent variables included demographic, disease-related, family support, medication related, and health care system variables.
Demographic variables included: age (in years, on the interview day); gender, marital status, categorized as married (in a stable relation) or unmarried (single, widowed or separated); race, selfreferred as White (including Asians) or non-White; religion was based on self-classification as religious or nonreligious; education was categorized as 4 or less years of schooling and more than 4 years of schooling; work status was categorized as employed (included self-employed) or not employed (retired, unemployed, on health-benefit, never employed, student and homemaker); per capita income was calculated according to patient's information regarding total family income divided by the number of people living on this income.
Disease related variables included: medical diagnosis (obtained through chart review, considering ILAE classification), 8 Medication related included number of AEDs (categorized as mono-or polytherapy), therapeutic complexity (measured by the EMTCI scores, according to the original instrument's scoring guide).
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The EMTCI is a specifically designed tool to assess medication regimen complexity in adult patients with epilepsy. EMTCI is a four-item questionnaire, which collects information on medication use, medication administration frequency, and special directions and actions to ensure that medications are taken as prescribed. The Brazilian-Portuguese version of the EMTCI, adapted for use in Brazil, has shown good reliability and validity. 12 Healthcare related variables included access to medication (public system or private), action taken when medication is not accessible (categorized as does not take medication or buys medication/obtains from alternative source), frequency of medical visits (expressed in days), difficulty to obtain physician's appointment (categorized by the patient as easy or difficult), unscheduled clinic visit (categorized as always available/never needed or rarely/never available), quality of medical care (categorized as very good/good or bad/no opinion) and perception of health status since initiating treatment in the clinic (much better/better or slightly better/no improvement/ does not know).
Statistical analysis
Statistical analysis was carried out with the Statistical Package for the Social Sciences (SPSS) 18.0 (SPSS Inc., Chicago, IL, USA). Association between treatment adherence and nominal independent variables was tested with Pearson's chi-square test or likelihood ratio statistics. Data were tested for normal distribution with the Kolmogorov-Smirnov test and for homogeneity of variances. Comparisons of means between high and moderateto-low adherence groups were performed with Student's t-test when variables were normally distributed; otherwise, nonparametric Mann-Whitney test was applied.
Backward stepwise multiple logistic regression analysis was used to identify factors associated with treatment non-adherence. Variables associated with non-adherence (p < 0.20) were included in the model. Model adequacy was measured with receiveroperating characteristics (ROC) under the curve area. Statistical tests were performed with a 5% significance level (p < 0.05).
Results

Demographics
We studied 385 patients, with ages ranging from 18 to 76 years (mean 39.7 AE 12.6 yrs), 53.5% women, 31.9% single, 22.6% widowed or divorced, 15.1% had at least some college education, 60.8% were self-classified as White, 92.7% declared a religious affiliation; 37.9% were employed (6.5% self-employed), monthly mean per capita income was R$627.25 (circa US$325.00).
Epilepsy features
Regarding epilepsy syndrome classification, 79.5% had focal symptomatic epilepsy, (54.5% had temporal lobe epilepsy and 34.5% mesial temporal sclerosis), 8.8% had focal cryptogenic epilepsy, 9.9% had generalized idiopathic epilepsy, and 1.8% had generalized cryptogenic epilepsy.
Mean disease duration was 22.4 years; mean treatment duration was 21.5 years. 40.3% of patients had been seizure-free in the previous 30 days; 79.0% had presented seizures in the 6 months preceding the interview. However, only 41.0% of the patients considered seizures to be not always or not at all controlled.
AED treatment
Regarding AED numbers, 71.1% of the patients were on a two to five AED polytherapy regimen (29.4% of patients were on a single AED, 36.1% on two AEDs and 28.3% on three AEDs); 55.8% of patients were on carbamazepine, 38.7% on clobazam and 35.3% on lamotrigine. Sixty-six percent of the patients did not adhere to treatment (Morisky-Green Test), 60.5% had moderate and 5.7% had low adherence levels. Patients attributed non-adherence to: forgetting doses (47.5%), lack of time to take AEDs (39.2%), worsening symptoms (9.0%), and symptom improvement (8.5%).
Comparison of independent variables between high and moderateto-low adherence groups is displayed in Table 1 .
Health care variables and social support issues
The majority of patients (60.8%) declared it was easy to schedule a clinic visit after the initial appointment, and that it was always possible to schedule an emergency appointment (89.8%). Mean interval between physician visits was 141.7 AE 81.6 days (range 15-360 days); 49.4% had clinic visits at 120-180 day (4-6-month) intervals. Most patients (93.3%) considered the medical consult as good or very good. 83.1% attributed improvement or great improvement in their health condition after starting treatment in the clinic.
96.1% of participants received free medication from the public service; 82.1% buy medication if free medication is not available. Treatment complexity mean, measured by EMTCI was 14.7 AE 8.0 points (range 2.0-44.0).
The majority of patients declared that they always (63.6%) or nearly always (9.4%) had family or friends support. We found no statistically significant association between family members or friends support and treatment adherence.
We found no statistically significant association between demographic features (gender, marital status, race, religion, education level and occupational status) and treatment adherence level on univariate analysis (Table 1) .
Adherence was significantly associated with seizure occurrence in the previous 30 days, seizure control, and treatment regimen (Table 1) . Compared with patients in the high adherence group, patients in the moderate-to-low adherence group reported a higher seizure frequency in the previous 30 days (64.7% vs. 50.0%), uncontrolled seizures (83.9% vs. 69.2%), and being on AED polytherapy (76.1% vs. 61.5%). Mean patients' age in the moderate-to-low adherence group was significantly lower (p < 0.001) than that of patients in the high adherence group. Treatment regimen complexity, assessed by the EMTCI, was significantly higher (p < 0.001) in the moderate-to-low adherence group.
Multiple regression analysis model included all factors with p < 0.20, namely: gender, race, seizure occurrence in the previous 30 days, controlled seizures, perception of seizure control, medication regimen, number of physicians visits, and treatment regimen complexity index (EMTCI). Multiple logistic regression analysis results are summarized in Table 2 . Four variables were significantly associated with treatment adherence: gender, age, seizure control status, and treatment regimen complexity. Nonadherence was less frequent among older patients; a 1-year increment in age was associated with a 3% decrease in treatment non-adherence probability. Non-adherence was also more common among individuals who had to follow more complex treatment regimens; a one-point increment in EMTCI score was associated with a 6% increase in treatment non-adherence probability.
Area under ROC curve was 0.69 (95% CI = 0.64-0.75; p = 0.000). Correct prediction of adherence and non-adherence model was 68.3%. Percentage of correct classification was 91.8% for nonadherence and 22.3% for adherence to treatment.
Discussion
In this study, 66.2% of patients with epilepsy had moderate to low level of adherence to treatment, as assessed by the MoriskyGreen Test. Other studies that used the same test have reported 59%, 13 58% 14 treatment adherence in people with epilepsy.
Another study, 15 using a different instrument to measure adherence, found a 68.5% non-adherence rate in outpatients with juvenile myoclonic epilepsy. Measuring adherence is a complex task. 16 In the absence of a gold standard, multiple tools are utilized to assess adherence. Pill or refill count may overestimate adherence, since patients may discard pills, instead of taking medication. 17 Computerized pharmacy databases are more informative of medication acquisition rather than intake. 18 Medication diaries are of limited use to evaluate adherence, since the majority of patients do not follow instructions or fill diaries immediately before physician appointments. 19 Patients' or caregiver's reports are subjective and may overestimate adherence. 18 Measuring AED plasma levels is invasive, and impractical for large populations. 20, 21, 29 Decreased medication levels in the postictal period have been associated with low adherence and breakthrough seizures. Medication intake under direct supervision can only be accomplished on once-daily regimens, in hospitalized patients or for patients under continuous nursing care. Adherence questionnaires are practical, inexpensive, easily applicable, and, therefore, commonly used in clinical practice and research.
16,22
The Morisky-Green Test has been widely used to assess treatment adherence in patients with other chronic diseases, thus allowing comparison of adherence between different patient populations. The Morisky-Green Scale relies solely on patient's report of perceived adherence. Patient's perception of adherence may be erroneous, especially in patients with memory impairment, such as people with epilepsy. 23 The Morisky-Green Scale has been referred to as blunt and naïve. 24 Additionally, it was originally validated in a population skewed toward Blacks (91%), women (70%), and patients with relatively little education (8 years mean). 10 Medication intake is not verified. However, it is internally valid, and is a quick and easy method to assess adherence. Non-adherence rates in other studies, assessed by the Morisky-Green Scale, ranged from 28% to 85.8%. [25] [26] [27] [28] [29] The lowest reported non-adherence rate (28%) was noted in a study with 61 adult patients treated with oral antineoplastic agents. 25 Adherence studies have also incorporated the use of prescription records to identify patients who were ordering medication less frequently than expected. 30 In our institution, patients receive free medication on a monthly basis, either by collecting the drugs directly at the hospital pharmacy or through a home-delivery system. If patients miss a clinic appointment, they will not be able to obtain medication unless they present to an unscheduled clinic appointment. Since the total number of pills is dispensed monthly, we were unable to use this measure to verify treatment adherence. We did not find a significant association between frequency of clinic appointments and adherence. We did not control for absenteeism; our study population included only patients who showed up for the clinic appointment. Since in our clinic all patients are allowed unscheduled appointments if they present unexpected changes in clinical condition or may run out of medication. In this scenario, frequency of clinic appointments would be more related to clinical condition, and less likely to be associated with treatment adherence. 31 We also did not find an association between friends and family support and adherence. We observed high levels of perceived friends and family support (around 72%) for both groups of adherent and non-adherent patients. Patients with controlled seizures reported less family and friends support than patients with uncontrolled seizures, underscoring the role of family and friends support in this patient group.
Employment status did not differ among low and high adherence patients groups. In fact, employment rate in this study was surprisingly high, considering the profile of a population of patients with very refractory epilepsy. We did not include patients with intellectual disabilities. Our patient population is therefore biased towards patients who might be more likely to work. Another caveat is that our methods considered self-employed patients were considered as employed. One may speculate that, since disability and disease benefits may be hard to obtain in Brazil, and may also provide insufficient funds to allow subsistence, patients with refractory epilepsy may need to obtain additional income in the informal market, sometimes helping a family member. These patients will consider themselves employed and generating income. These issues should be investigated with appropriate methodology.
In the present study, the most common reasons for nonadherence to treatment regimens were forgetting to take the medication. Non-adherence was attributed to forgetting to take medication for 47.5% of patients, and lack of time to take medications for 39.2% of patients. A postal survey study with 661 adults assessed non-adherence and consequences of inadequate AED treatment compliance in epilepsy patients. 32 This survey consisted of 10 direct questions on medication dosing and possibility of seizure occurrence after omitted doses. 66% of patients reported taking more than four pills per day, 71% reported missing a dose of medication at least once, 32% informed doctors when they missed doses, and 45% reported seizure occurrence as a consequence of missing an AED dose.
Cognitive and memory problems have also been found to be a significant reason for non-adherence than unwillingness or carelessness to take medication. 33 In that study, the overwhelming majority of patients was willing to regularly take medication.
Self-reported AED adherence was assessed with an online survey in which 408 epilepsy patients were asked whether or not they missed or stopped a AED dose in the previous week, month, and 3 months, 6 29% of patients were classified as non-adherent, and 72% reported forgetting doses as the main AED non-adherence reason. 6 Brazilian studies assessing treatment adherence with the Morisky-Green Test have also reported forgetting doses and lack of time as the main non-adherence reason among patients with chronic diseases other than epilepsy. 27, 34 Through logistic regression analysis, we found a statistically significant association between treatment non-adherence age, gender, seizure control status and treatment regimen complexity, as measured by the EMTCI. Women are more adherent to treatment and are more accepting of the diagnosis, while men tend to prioritize work and delay seeking medical care to avoid unemployment. [35] [36] [37] In our study, non-adherence was more common among younger patients. One-year increments were associated with a 3% decrease in treatment non-adherence probability. A literature review of human immunodeficiency virus (HIV)-positive patients showed that treatment adherence increased in ages up to 75 years. 38 Treatment complexity (EMTCI) was also significantly associated with treatment non-adherence. A one-point increase in the EMTCI was associated with a 6% increase in treatment non-adherence probability. The impact of the complexity of treatment regimens on patient adherence is well documented.
1,32,39-42 Treatment complexity affects not only newly diagnosed patients, but also those receiving long-term treatments. A study with 661 epilepsy patients treated for a 10-year period showed a relationship between forgetting to take medications and seizure occurrence. This study also showed that increasing treatment complexity, increased the likelihood of the patient forgetting to take medications, and consequent increase in seizure occurrence probability. 37 In epilepsy and other chronic diseases, such as high blood pressure and acquired immune deficiency syndrome (AIDS), increasing treatment regimen complexity is associated with decreased treatment adherence. As treatment complexity increases, patients' understanding of the regimen decreases, leading to failure to take medications as prescribed. [43] [44] [45] [46] Treatment complexity may also interfere with symptom control. In this study, seizure frequency in the previous 30 days, as well as seizure control status were associated with treatment nonadherence, but only seizure control was retained in the final regression model. Treatment non-adherence probability was lower among patients with seizure control. A study that compared two epilepsy patient groups (non-adherent patients, n = 298; adherent patients, n = 110) also found non-adherence to be associated with reduced seizure control. 6 In that study, patients who reported loss of seizure control loss, had undergone changes in medication dose (70%), had been switched to a new medication (61%), or had another medication added to the treatment regimen (56%). 6 Low treatment adherence is strongly associated with uncontrolled seizures among epilepsy patients, and with symptom recrudescence in other chronic diseases. 13 It has been shown that seizure occurrence after AED dose omission will result in improved treatment adherence. 47 Although it is widely accepted that non-adherence leads to poor seizure control, our findings also suggest that uncontrolled seizures may, paradoxically, contribute to non-adherence. Treatment non-adherence in people with epilepsy increases the risk of uncontrolled seizures, injuries, emergency room visits, hospital admissions, occurrence of status epilepticus and SUDEP, underscoring the need for implementation of strategies to improve adherence. Intensive reminders and implementation of intention interventions appear promising to enhance adherence in people with epilepsy receiving AEDs. 48 Moreover, strategies designed to improve adherence should not be limited to patient related factors, but should also encompass provider and health care system related factors. 24 Our study adds to the scant literature of treatment adherence in outpatient epilepsy patients in Brazil. The Morisky-Green Test, albeit generic and biased to patient's adherence perception, allows comparison of adherence levels in different patient populations. 24 Our results show that treatment non-adherence rates for epilepsy patients in Brazil were similar to those for patients in other countries. It should be kept in mind, however, that our patient population was heavily biased to heavily medicated patients with difficult-to-control seizures. Caution should be exercised in extrapolating results to different samples of people with epilepsy.
Multiple logistic regression analysis of patients, disease, treatment regimen, and social support features showed that variables that best explained treatment non-adherence were age, gender, treatment complexity and seizure control status. Strategies designed to improve treatment adherence should address peculiarities associated with younger ages and male gender. Physicians should be made aware that prescription of less complex treatment regimens may result in better treatment adherence, and therefore better seizure control. Patients with medically refractory epilepsy need increasing medication doses and AED polytherapy. The challenge in adjusting AED treatment in this population is to minimize treatment complexity, to increase chances for treatment adherence.
